Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 5/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 5/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.41 |
| ▸ | MYLK4 | Q86YV6 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030076 | 0.88 | AKT2 (0.50) | AKT2HTR2AHRH1AKT1ROCK2 | |
| SCHEMBL3019602 | 0.84 | AKT2 (0.63) | AKT2HRH1AKT1ROCK2ROCK1 | |
| SCHEMBL3026285 | 0.83 | AKT2 (0.52) | AKT2HTR2AHRH1SLC6A2SLC6A4 | |
| SCHEMBL1979011 | 0.83 | AKT2 (0.50) | AKT2HTR2AHRH1AKT1ROCK2 | |
| SCHEMBL1977801 | 0.83 | ROCK2 (0.53) | AKT2HTR2AHRH1SLC6A4AKT1 | |
| SCHEMBL1978888 | 0.83 | AKT2 (0.65) | AKT2HTR2AHRH1AKT1ROCK2 | |
| SCHEMBL1978444 | 0.81 | ROCK2 (0.54) | AKT2HTR2AHRH1SLC6A2SLC6A4 | |
| SCHEMBL1980599 | 0.81 | ROCK2 (0.55) | AKT2HTR2AHRH1AKT1ROCK2 | |
| SCHEMBL1978972 | 0.81 | AKT2 (0.51) | AKT2AKT1ROCK2CYP2C9CYP2C19 | |
| SCHEMBL1976907 | 0.80 | SLC6A2 (0.52) | AKT2HTR2AHRH1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ERBB2, ABL1, GRK2 | AKT2 88/4885HTR2A 56/4885HRH1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.